| Document |
Document Title |
|
WO/2022/112207A1 |
The present invention provides novel compounds having the general formula wherein A1 to A4, X1, Rx, Ry, Cy, L and R1 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/112072A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.
|
|
WO/2022/112345A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for...
|
|
WO/2022/112140A1 |
The present invention provides novel compounds having the general formula (I) wherein Al to A4, Li, L2, R1 and R2 are as described herein, compositions including the compounds and methods of using the compounds for the treatment of HBV i...
|
|
WO/2022/112352A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for...
|
|
WO/2022/112490A1 |
The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositio...
|
|
WO/2022/114164A1 |
Provided is a compound which is useful as an active ingredient for a pharmaceutical composition for treating cancer associated with the activation of an immunocyte or cancer having resistance to an anti-PD-1 antibody/anti-PD-L1 antibody ...
|
|
WO/2022/111605A1 |
The present disclosure relates to an aryl or heteroaryl substituted 5-membered aromatic heterocyclic compound and the use thereof. In particular, provided is a compound as shown in formula I or a pharmaceutically acceptable salt thereof,...
|
|
WO/2022/114189A1 |
Provided is a compound that exerts an anticancer effect based on the inhibition of CHK1. The present disclosure has been completed based on the finding that a compound represented by formula (1) or a pharmaceutically acceptable salt ther...
|
|
WO/2022/112205A1 |
The present invention provides novel compounds having the general formula (I) wherein A1 to A4, X1, X2 and R1 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/115879A1 |
The present disclosure relates to compounds and pharmaceutical compositions thereof, and methods of using the compounds and compositions in therapy, such as methods of treating cancer.
|
|
WO/2022/112139A1 |
The present invention provides novel compounds having the general formula (I) wherein R1 to R3 are as described herein, or a pharmaceutically acceptable salt thereof, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/111513A1 |
Provided are an aromatic compound represented by formula A or a pharmaceutically acceptable salt thereof, and a preparation method therefor and the use thereof. The aromatic compound has a good inhibitory effect on KRAS, especially KRAS ...
|
|
WO/2022/107724A1 |
The present invention provides: a novel azetidinone derivative having excellent herbicidal activity, or a salt thereof; an herbicide containing the same as an active ingredient; and a production intermediate. Provided are: an azetidinone...
|
|
WO/2022/106680A1 |
The present invention provides novel compounds having the general formula: (Formula I) wherein A1 to A4, X, Cy and R1 are as described herein, compositions including the compounds and methods of using the compounds as HBsAg inhibitors fo...
|
|
WO/2022/105771A1 |
The present invention relates to a nitrogen-containing heterocyclic derivative, and a preparation method therefor and a medical application thereof. Specifically, the present invention relates to a nitrogen-containing heterocyclic deriva...
|
|
WO/2022/107144A1 |
The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of a disorder associated with binding of IGF2BP1 to an RNA in a subject in need thereof ...
|
|
WO/2022/105908A1 |
The present invention relates to an EGFR inhibitor having a structure of formula (I) and a preparation method therefor, a pharmaceutical composition containing the EGFR inhibitor, a use of the pharmaceutical composition as the EGFR inhib...
|
|
WO/2022/106375A1 |
The present invention provides novel compounds having the general formula (I) wherein A, L, and B are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/106589A1 |
The present invention provides novel compounds having the general formula (I) wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/101265A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2022/103899A1 |
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
|
|
WO/2022/100099A1 |
An organic compound, a mixture, a composition and an organic electroluminescence device. The organic compound has a high extinction coefficient in the ultraviolet region; has a high refractive index in the visible light region; can be us...
|
|
WO/2022/101352A1 |
The present invention relates to novel compounds that bind to the prostate-specific membrane antigen (PSMA)-binding and their use in the diagnosis and treatment of certain diseases where PSMA is upregulated.
|
|
WO/2022/103031A1 |
Provided is a triazine or pyrimidine derivative that contributes to a substantial improvement in lifespan of an organic electroluminescent element by effectively absorbing high energy in the UV range from an external light source to mini...
|
|
WO/2022/100716A1 |
Disclosed are a cyanine compound, a dye containing the cyanine compound, and the use of the cyanine compound. The cyanine compound has a structure of general formula I, wherein X is selected from a group consisting of C(CH3)2, O, S and S...
|
|
WO/2022/100625A1 |
The present invention relates to novel compounds effectively antagonizing LPAR, which are a compound as shown in formula (I), or a stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug of the compound as shown in fo...
|
|
WO/2022/101412A1 |
Provided herein are substituted 1,1,1,3,3,3-hexafluoropropan-2-yl 6-azaspiro[2.5]octane-6-carboxylate compounds and pharmaceutical compositions comprising said compounds. The compounds and compositions provided herein are useful as inhib...
|
|
WO/2022/099658A1 |
Disclosed in the present invention are a cyanine compound, a dye containing the cyanine compound, and an application of the cyanine compound. The cyanine compound has the structure of general formula I. X is selected from a group consist...
|
|
WO/2022/103960A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2022/101771A1 |
The present invention is directed to compounds and pharmaceutically acceptable salts thereof, immunoconjugates, radioimmunoconjugates thereof, pharmaceutical compositions containing said compounds and immunoconjugates, radioimmunoconjuga...
|
|
WO/2022/100623A1 |
Disclosed is a new class of compounds that effectively antagonize LPAR, which are compounds represented by the following formula, or a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug of the compounds r...
|
|
WO/2022/099044A1 |
Disclosed herein are compounds of Formula I": or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering...
|
|
WO/2022/099011A1 |
Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is...
|
|
WO/2022/096869A1 |
A TADF dendrimer of formula (I), (Ar1)m-(Ar2)-(X)n, wherein: Ar2 is a pyridine, pyrimidine, pyrazine, pyridazine, triazine or tetrazine ring group; m is from 1 to 5; n is 0, 1 or 2; each Ar1 is a six-membered aromatic or heteroaromatic r...
|
|
WO/2022/095989A1 |
The present invention relates to compounds which have cancer treatment activity, and also relates to a preparation method for such compounds and a pharmaceutical composition comprising same.
|
|
WO/2022/099071A1 |
This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3'-((2-(difluoromethyl)-7-((3-hydroxypyrr
olidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2'-d
imethyl-[1,...
|
|
WO/2022/099066A1 |
Disclosed herein are compounds of Formula I': or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering...
|
|
WO/2022/096411A1 |
k series of substituted dicyclopropylmethyl derivatives as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory a...
|
|
WO/2022/099018A1 |
The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3'-(3-(((R)-3-hydroxypyrrolidin-1-yl)meth
yl)-1,7-naphthyridin-8-ylamino)-2,2'-dimethylbiphenyl-3-yl)b
enzo[d]oxazol-5-yl)methyl)pyrrolidine-...
|
|
WO/2022/097626A1 |
A high-efficiency, near-infrared light-emitting organic EL element can be provided by using a compound given by the general formula. At least one of R1-R4 is *-Ar-D, or R1 and R2, R2 and R3, or R3 and R4 are bonded to each other to form ...
|
|
WO/2022/094244A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (I SR) and for treating related diseases, disorders, and conditions.
|
|
WO/2022/091123A1 |
The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly cancer stem cells. Particularly, the invention relates to compounds of Formula (I) to (IV) for the treatment of cancer.
|
|
WO/2022/091056A1 |
The present invention relates to novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds that are Interleukin-17 (IL-17) inhibitors, processes for their preparation, pharmaceutical compositions, and me...
|
|
WO/2022/092141A1 |
The present invention provides: a compound, or a pharmaceutically acceptable salt thereof, having an antiviral activity and represented by formula (I); and a pharmaceutical composition containing the same. (In the formula, the broken lin...
|
|
WO/2022/092084A1 |
The present invention provides a novel fused heterocycle derivative or an agriculturally acceptable salt thereof and an herbicide containing the same as an active ingredient.　Provided are a fused heterocycle derivative represented by g...
|
|
WO/2022/089398A1 |
A compound of formula (I) having the activity of inhibiting HPK1 kinase and a pharmaceutical composition comprising the compound. Also provided are the use of the compound in the prevention and/or treatment of cancers, tumors, inflammato...
|
|
WO/2022/090711A1 |
The present invention relates to compounds of formula I shown below: wherein R1 and R2 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical comp...
|
|
WO/2022/094218A1 |
The present disclosure provides processes for the synthesis of organic compounds, in particular processes for the synthesis of heteroaryl-substituted sulfur(VI) compounds by nucleophilic aromatic substitution.
|
|
WO/2022/093850A1 |
Provided is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, that is a modulator of 5-HT2A and can be used in treating diseases and disorders associated with 5-HT2A serotonin receptor expression and/or activity. T...
|
